News

Digital health company Eko has been awarded $2.7 million from the National Institutes of Health (NIH) to develop an artificial intelligence (AI)-based algorithm that can detect pulmonary hypertension (PH) and classify its severity. The algorithm will analyze data from two common, noninvasive heart tests collected via Eko’s digital smart…

A new study has found that there are nine metabolites — molecules that take part in metabolism — in the blood that can tell pulmonary arterial hypertension (PAH) linked to systemic sclerosis from idiopathic PAH, the label given when the disease is due to an unknown cause. Researchers also…

Adempas (riociguat), an approved therapy for adults with pulmonary arterial hypertension (PAH), was well-tolerated in children and adolescents with PAH, with no new safety signals, according to data from PATENT-CHILD — the first pediatric trial of the therapy. The medication, used off-label for pediatric PAH patients with doses tailored…

Up to two years of treatment with sotatercept safely maintained gains in heart function and physical abilities in people with pulmonary arterial hypertension (PAH), according to details of the PULSAR study extension phase. Further, participants who were initially assigned a placebo in the Phase 2 controlled trial, and switched…

Mice that lack a protein called AMPK in the muscle around their blood vessels develop a lethal disease that appears very similar to persistent pulmonary hypertension of the newborn (PPHN), suggesting that AMPK may be a useful therapeutic target in this disease, according to a new study. “This study…

Preterm babies who grow with too little amniotic fluid (also called waters), or are born too small for their age, are at greater risk of developing pulmonary hypertension in the first two weeks of life, a meta-analysis study found. Babies with early pulmonary hypertension (PH) were more likely to…

Scores on standardized risk assessments showed a clear treatment effect with Orenitram (treprostinil) after three months in a pulmonary arterial hypertension (PAH) clinical trial, with patients showing risk score improvements being less likely to have clinical worsening later on. The results of this new analysis suggest early changes…

The Mayo Clinic will use a digital clinical trial platform developed by Triall in an upcoming pulmonary arterial hypertension (PAH) study. The platform will support all core activities related to the study, including data capture, document management, monitoring, and electronic consent forms to safeguard the integrity of…

The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have published a new set of guidelines for the diagnosis and management of pulmonary hypertension (PH). These guidelines simplify diagnostic criteria for PH, emphasizing the importance of early disease detection and the expedited referral of high-risk patients…

A protein called LTBP-2 was found to be significantly elevated in people with pulmonary arterial hypertension (PAH), according to a new analysis — and the data suggest that measuring its levels may help predict long-term survival among PAH patients. Further, blood levels of LTBP-2 were also able to predict…

Measuring blood levels of a certain type of DNA released by damaged cells — called cell-free DNA — may be a way to monitor disease severity in people with pulmonary arterial hypertension (PAH), a study found. The study’s researchers from the National Institutes of Health (NIH) say the test…

Blood levels of IL-6 and PTX3 — two inflammatory proteins — could serve as prognostic biomarkers in people with pulmonary hypertension (PH) associated with left-sided heart disease, a study suggests. Higher levels of both were linked to a greater risk of dying and higher levels of NT-proBNP, a known…